Expanding access to HAART: a cost-effective approach for treating and preventing HIV

Objective:HIV continues to present a substantial global health burden. Given the high direct medical costs associated with the disease, prevention of new transmission is an important element in limiting economic burden. In addition to providing therapeutic benefit, treatment with HAART has potential to prevent transmission of HIV. The objective in this study was to perform an economic evaluation of the incremental net benefit associated with an intervention to expand treatment with HAART in British Columbia, Canada. Design:A mathematical model describing transmission of HIV, integrated with a microsimulation model describing the clinical and economic course of HIV. Methods:The primary outcome was the incremental net benefit of expanding treatment with HAART from 50 to 75% of clinically eligible individuals in British Columbia, assuming a willingness-to-pay threshold of US$ 50 000 per quality-adjusted life year. Direct medical costs included were antiretroviral and nonantiretroviral medications, hospitalizations, physician visits, and laboratory tests. The mathematical and microsimulation models were based on patient characteristics observed in British Columbia. Longitudinal data described health services utilization, clinical progression, and survival for all individuals receiving treatment for HIV in British Columbia. Results:Over 30 years, the HAART expansion scenario was associated with a net benefit of US$ 900 million (95% confidence interval US$ 493 million to 1.45 billion). Conclusion:Increasing the HAART treatment rate from 50 to 75% of clinically eligible individuals in British Columbia appears to be a cost-effective strategy based on this model. These cost-effectiveness results are consistent with public health objectives: all individuals who are eligible for an established life-saving treatment should receive it.

[1]  Andrew H. Briggs,et al.  Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.

[2]  Matthias Egger,et al.  Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis , 2009, AIDS.

[3]  Christopher Dye,et al.  Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model , 2009, The Lancet.

[4]  R. Siliciano,et al.  Human immunodeficiency virus. , 2009 .

[5]  A. Levy,et al.  Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. , 2008, The Journal of infectious diseases.

[6]  J. Salomon,et al.  Evaluating the impact of antiretroviral therapy on HIV transmission. , 2008, AIDS.

[7]  T. Déirdre Hollingsworth,et al.  Variation in HIV-1 set-point viral load: Epidemiological analysis and an evolutionary hypothesis , 2007, Proceedings of the National Academy of Sciences.

[8]  Alan Y. Chiang,et al.  Generalized Additive Models: An Introduction With R , 2007, Technometrics.

[9]  S. Blower,et al.  Narrative Review: Antiretroviral Therapy to Prevent the Sexual Transmission of HIV-1 , 2007, Annals of Internal Medicine.

[10]  Bas Groot Koerkamp,et al.  Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  David Wilson,et al.  HIV EPIDEMIOLOGY : A REVIEW OF RECENT TRENDS AND LESSONS , 2007 .

[12]  C. del Rio,et al.  The Economic Burden of HIV in the United States in the Era of Highly Active Antiretroviral Therapy: Evidence of Continuing Racial and Ethnic Differences , 2006, Journal of acquired immune deficiency syndromes.

[13]  S. Chick,et al.  A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.

[14]  Evan Wood,et al.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic , 2006, The Lancet.

[15]  Neil M Ferguson,et al.  Modelling the Impact of Antiretroviral Use in Resource-Poor Settings , 2006, PLoS medicine.

[16]  A. Levy,et al.  The direct costs of HIV/AIDS care. , 2006, Lancet. Infectious Diseases (Print).

[17]  S. Wood.  Generalized Additive Models: An Introduction with R , 2006 .

[18]  R. Hogg,et al.  Drastic elevations in mortality among female injection drug users in a Canadian setting , 2006, AIDS care.

[19]  Andrew Briggs,et al.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.

[20]  R. Hogg,et al.  Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. , 2003, AIDS.

[21]  Evan Wood,et al.  Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? , 2003, AIDS.

[22]  R. Hogg,et al.  Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[23]  Niklas Zethraeus,et al.  Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies , 2003, PharmacoEconomics.

[24]  H. Gershengorn,et al.  Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? , 2002, The Lancet. Infectious diseases.

[25]  M. Schechter,et al.  Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[26]  Milton C Weinstein,et al.  Comparison of Health State Utilities Using Community and Patient Preference Weights Derived from a Survey of Patients with HIV/AIDS , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  M. Schechter,et al.  Impact of HIV Infection on Mortality in a Cohort of Injection Drug Users , 2001, Journal of acquired immune deficiency syndromes.

[28]  Hiv Survival,et al.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.

[29]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[30]  D Y Lin,et al.  Methods for analyzing health care utilization and costs. , 1999, Annual review of public health.

[31]  R. Pomerantz.  Residual HIV-1 disease in the era of highly active antiretroviral therapy. , 1999, The New England journal of medicine.

[32]  R. Hogg,et al.  Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[33]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[34]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[35]  B. Yip,et al.  Antiviral effect of double and triple drug combinations amongst HIV‐infected adults: lessons from the implementation of viral load‐driven antiretroviral therapy , 1998, AIDS.

[36]  J. Wasserheit,et al.  The dynamic topology of sexually transmitted disease epidemics: implications for prevention strategies. , 1996, The Journal of infectious diseases.

[37]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[38]  E. Tramont,et al.  The human immunodeficiency virus. , 1991, Dermatologic clinics.

[39]  G. Torrance.  Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.

[40]  K. Evang.  [Health planning]. , 1966, Boletin de la Oficina Sanitaria Panamericana. Pan American Sanitary Bureau.